Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells

Hung-Chen Chen1☯, Pei-Yi Chen2☯, Ming-Jiuan Wu3, Mi-Hsueh Tai1, Jui-Hung Yen1*  
1 Department of Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan, 2 Center of Medical Genetics, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, 3 Department of Biotechnology, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan  
☯ These authors contributed equally to this work.  
* imyenjh@mail.tcu.edu.tw

Abstract  
Tanshinone IIA, one of the most pharmacologically bioactive phytochemicals isolated from Salvia miltiorrhiza Bunge, possesses several biological activities such as anti-inflammation, anti-cancer, neuroprotection and hypolipidemic activities. In this study, we aim to investigate the hypocholesterolemic effect of tanshinone IIA in hepatic cells. We demonstrated that tanshinone IIA significantly increased the amount of low-density lipoprotein receptor (LDLR) and LDL uptake activity in HepG2 cells at the post-transcriptional regulation. We further demonstrated that tanshinone IIA inhibited the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA and mature protein, which may lead to an increase in the cell-surface LDLR in hepatic cells. We further identified a regulatory DNA element involved in the tanshinone IIA-mediated PCSK9 down-regulation, which is located between the -411 and -336 positions of the PCSK9 promoter. Moreover, we found that tanshinone IIA markedly increased the nuclear forkhead box O3a (FoxO3a) level, enhanced FoxO3a/PCSK9 promoter complexes formation and decreased the PCSK9 promoter binding capacity of hepatocyte nuclear factor 1α (HNF-1α), resulting in suppression of PCSK9 gene expression. Finally, we found that the statin-induced PCSK9 overexpression was attenuated and the LDLR activity was elevated in a synergic manner by combination of tanshinone IIA treatment in HepG2 cells. Overall, our results reveal that the tanshinone IIA modulates LDLR level and activity via down-regulation of PCSK9 expression in hepatic cells. Our current findings provide a molecular basis of tanshinone IIA to develop PCSK9 inhibitors for cholesterol management.

Introduction  
Epidemiological studies have demonstrated that elevated circulating triglyceride-rich remnant lipoproteins and high concentrations of plasma low-density lipoprotein cholesterol (LDL-C) are directly correlated with the risk of atherosclerosis and cardiovascular disorders [1, 2]. The
The circulating LDL level is primarily determined by its rate of uptake through the LDL receptor (LDLR), a membrane glycoprotein in the human liver. Hepatic LDLR mediates the internalization of receptor-bound LDL particles and delivers the complex to the endosomes for degradation, and the LDLR then returns to the cell membrane. The free cholesterol is further metabolized to bile acids for excretion in hepatic cells [3]. Thus, the hepatic expression of LDLR plays a critical role in removing plasma LDL and is important in modulating cholesterol homeostasis. Raising the level of the cell-surface LDLR and receptor activity to increase the cholesterol clearance is an efficient way to reduce LDL levels in the bloodstream [4].

The level of LDLR is modulated in cells at transcriptional and post-transcriptional regulation [5]. LDLR transcription is predominantly activated by the transcription factors sterol response element binding proteins (SREBPs), especially nuclear SREBP1 or SREBP2 proteins, which bind to sterol regulatory elements (SREs) within the LDLR promoter [6]. In addition to the transcriptional regulation of LDLR, the proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important post-transcriptional regulator for modulating the amount of LDLR protein. The PCSK9 protein is translated as an approximately 74 kDa precursor protein and is processed into a 60 kDa secreted mature protein [7]. The secreted PCSK9 protein is an identified subtilisin-related serine protease that binds LDLR, blocks LDLR recycling and promotes LDLR degradation in the lysosome [8]. Thus, PCSK9 expression controls the LDLR level and cholesterol homeostasis. Individuals with loss-of-function PCSK9 mutations exhibit reductions in LDL-C levels and a risk of coronary heart disorders [9]. In recent clinical trials, monoclonal antibodies against PCSK9 caused a decrease in the plasma LDL-C levels of patients with hypercholesterolemia [10]. The inhibition of PCSK9 function might be expected to serve as a novel approach to modulate hepatic LDLR levels and manage lipid metabolism [11, 12].

PCSK9 gene expression was regulated by several transcription factors such as SREBPs, hepatocyte nuclear factor 1α (HNF-1α) and forkhead box O3 (FoxO3) [13–15]. Activation of the SREBP pathway has been reported to increase both LDLR and PCSK9 transcriptional activities. PCSK9, as well as LDLR, contain SREs in their promoters that respond to alterations in cellular cholesterol levels through SREBP-dependent pathways. The PCSK9 promoter interacts with SREBP2 or SREBP1c, which stimulates PCSK9 gene expression [16]. The transcription factor HNF-1α was also found to bind a DNA element within the PCSK9 promoter and to activate PCSK9 expression in hepatic cells. The attenuation of nuclear HNF-1α levels resulted in the down-regulation of PCSK9 expression, consequently increased the amount of cell-surface LDLR and elevated the receptor activity in hepatic cell lines [14, 17]. Recently, the FoxO3a protein, a forkhead transcription factor, has been reported as a negative regulator of PCSK9 gene expression through epigenetic modulation. The FoxO3a protein interacts with the insulin-response element (IRE) within the PCSK9 promoter, recruiting the sirtuin-6 (Sirt6) protein to deacetylate histones and reducing the promoter binding capacity of HNF-1α, which leads to a suppression of PCSK9 gene expression in hepatic cells [15].

The dried root of *Salvia miltiorrhiza* Bunge, also known as Danshen, is a traditional Chinese herbal medicine that has been used in Asian countries for the treatment of coronary artery disease, myocardial infarction, stroke, atherosclerosis and cerebrovascular disorders [18, 19]. Tanshinone IIA (Fig 1A) is one of the most pharmacologically bioactive constituents isolated from Danshen and possesses numerous biological activities for the prevention or treatment of inflammation processes, hepatic fibrosis, neurodegenerative disorders, cancer and cardiovascular diseases [20, 21]. Several studies have suggested that tanshinone IIA modulates lipid metabolism. In animal studies, it has been demonstrated that tanshinone IIA attenuates atherosclerosis in hypercholesterolemic rats [22] and hyperlipidemic rabbits [23]. Tanshinone IIA prevented foam cell formation and oxidized-LDL (oxLDL) uptake in macrophages [24], reduced oxLDL-induced scavenger receptor expression through activation of the ERK/Nrf2/
HO-1 pathway and regulated the cholesterol balance [25]. However, the underlying mechanisms of tanshinone IIA’s regulation of cholesterol homeostasis remain unclear.

In the present study, we aim to investigate the hypocholesterolemic effects of tanshinone IIA and underlying mechanisms in HepG2 cells, which are generally used as a model to study the human LDL-C metabolism [26]. We investigated the effect of tanshinone IIA on the LDLR level, LDL uptake activity and PCSK9 gene expression in HepG2 cells. We also focus on the effects of combining tanshinone IIA and lovastatin or simvastatin on PCSK9 gene expression and LDLR activity in HepG2 cells.

Materials and Methods

Chemicals

Tanshinone IIA (purity ≥ 97%), dimethyl sulfoxide (DMSO), non-essential amino acids (NEAA), mevinolin (lovastatin) and other chemicals were purchased from Sigma-Aldrich Co. (St. Louis, MO), unless otherwise indicated. Gibco fetal bovine serum (FBS) was purchased from Thermo Fisher Scientific, Inc. (Rockford, IL, USA). Simvastatin was purchased from Tokyo Chemical Industry (Toshima, Kita-Ku, Tokyo, Japan).

Cell culture and treatment of cells with tanshinone IIA

HepG2 cells were obtained from the Bioresource Collection and Research Center (Hsinchu, Taiwan) and maintained in DMEM medium containing 10% fetal bovine serum (FBS). The cells were seeded and cultured in normal serum medium overnight; then, the medium was changed to DMEM supplemented with 5% lipoprotein-deficient serum (LPDS) [27] and was cultured for 24 h. The cells were then treated with vehicle (0.1% DMSO) or tanshinone IIA for 24 h. For statin treatment, the HepG2 cells were pretreated with the vehicle or tanshinone IIA for 1 h and then incubated with 1 μM lovastatin or simvastatin for an additional 24 h.

Fig 1. Effect of tanshinone IIA on the cell viability in HepG2 cells. (A) Chemical structure of tanshinone IIA. (B) HepG2 cells were cultured in LPDS medium and treated with the vehicle (0.1% DMSO) or tanshinone IIA (1–20 μM) for 24 h. Cell viability was measured using an MTT assay. The data represent the mean ± SD from three independent experiments.

doi:10.1371/journal.pone.0162414.g001
MTT assay
The MTT assay was used to determine the cell viability [28]. The cells were treated with the vehicle or tanshinone IIA (1–20 μM) for 24 h and then incubated with MTT reagent (1 mg/mL) at 37°C for 3 h. The purple formazan crystals were dissolved in DMSO and the absorbance was measured at 550 nm.

RNA extraction and reverse transcription quantitative PCR (RT-Q-PCR) analysis
Cells were cultured in LPDS-containing medium as described above and treated with the vehicle or tanshinone IIA (5 and 10 μM) for 24 h. The RNA was extracted using the Total RNA mini Kit (Geneaid, Taipei, Taiwan) according to the manufacturer’s instructions. Reverse transcription was carried out using the High-Capacity cDNA reverse transcription kit (Thermo Fisher Scientific). Quantitative real-time PCR was performed using a reaction mixture containing cDNA, specific primers [LDLR, 5’-AGTTGGCTGGTTAATGTA-GA-3’ (forward) and 5’-TGATGGGTTGATCTGACAGT-3’ (reverse); PCSK9, 5’-GCTGAAGCTGTTCCAGTTCT-3’ (forward) and 5’-AATGGCCTAGACACCTCAG-3’ (reverse); HMGCoA reductase (HMGCR), 5’-TGATGGACCTTTCCAGAAGCAG-3’ (forward) and 5’-CTAAAATTGC-CATTCCCAAGG-3’ (reverse); GAPDH, 5’-CATGAGAAGTTAGACACCT-3’ (forward) and 5’-AGTCCTTCCACGATACAAAG-3’ (reverse)] [17] and Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific). PCR amplification was carried out in a Roche LightCycler®-480 Real-Time PCR System. The real-time PCR conditions were 50°C for 2 min, 94°C for 4 min, 45 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min. The ΔΔCt method was used for data analysis [29]. The amount of mRNA was normalized to the GAPDH level in the same samples.

Western blot analysis
Cells were seeded as described above, the medium was then changed to a DMEM/LPDS medium and the vehicle or tanshinone IIA was added for an additional 24 h. For the extraction of total cellular proteins, the cells were harvested using RIPA buffer (Thermo Fisher Scientific). For nuclear extract preparation, the cells were harvested using the NE-PER nuclear and cytoplasmic extraction reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. Total cellular lysates (20 μg) and nuclear extracts (20 μg) were analyzed by 10% SDS-PAGE and transferred onto a PVDF membrane (PerkinElmer, Boston, MA, USA). The blots were incubated with the following specific primary antibodies at 4°C for 24 h: anti-LDLR (Novus Biologicals, Littleton, CO, USA), anti-PCSK9, anti-HDAC2 (GeneTex, Irvine, CA, USA), anti-N-terminus of SREBP2 (Cayman, Ann Arbor, MI, USA), anti-HNF-1α (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-FoxO3a (Cell Signaling Technology, Danvers, MA) or anti-β-actin (Sigma-Aldrich). The blots were incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology) at 37°C for 1 h. The proteins were detected using the Amersham ECL™ Prime Western Blotting Detection Reagent, and the signal was visualized on Amersham Hyperfilm™ ECL (GE Healthcare, Buckinghamshire, UK).

Analysis of cell-surface LDLR
The cell-surface LDLR was detected by flow cytometry analysis as previously described [17]. Briefly, the cells were seeded as described above and treated with the vehicle or tanshinone IIA for 24 h. The cells were scraped, washed with phosphate-buffered saline (PBS) and then incubated with PBS containing 5% bovine serum albumin (BSA) at room temperature for 30 min.
The anti-LDLR antibody was added and incubated at 37°C for 1 h. The cells were washed with PBS and incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG (Thermo Fisher Scientific) at room temperature for 30 min. The cells were analyzed by flow cytometry (FACScan, BD Biosciences, San Jose, CA, USA). The data were calculated using Cell Quest Pro software (BD Biosciences), and the cell-surface LDLR was expressed as the relative percentage of the geometric mean fluorescence intensity.

Measurement of LDL uptake
The amount of LDL uptake was measured as previously described [17, 30]. Briefly, the cells were treated with vehicle or tanshinone IIA for 24 h, which was then replaced with fresh serum-free medium and incubated with 10 μg/mL BODIPY FL-LDL (Thermo Fisher Scientific) at 37°C for 24 h. The cells were detached, washed and re-suspended in PBS and examined by flow cytometry. Data were acquired from 10,000 cells (counts). The LDL uptake data were expressed as the relative percentage of the geometric mean fluorescence intensity.

Plasmid transfection and luciferase reporter assay
Reporter plasmids containing the PCSK9 promoter (from −1459 to −4, relative to the A of the translation initiation codon ATG), the LDLR promoter (from −1480 to +40, relative to the transcription start site), and the serial deletion regions of the PCSK9 promoter for the luciferase reporter assay were designated and constructed as previously described [17]. HepG2 cells were co-transfected with the indicated reporter plasmids and the Renilla luciferase control vector (Promega) using the Lipofectamine regent (Thermo Fisher Scientific) according to the manufacturer's instructions. After transfection, the cells were treated with vehicle or tanshinone IIA for 24 h. The luciferase activities were measured using the Dual-Luciferase Reporter Assay System Kit (Promega), and the intensities were normalized to the Renilla luciferase activity.

Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the ChIP Assay Kit (Millipore, Billerica, MA, USA) as previously described [17, 31]. Briefly, the chromatin isolated from cells was sheared by sonication, and 1% of the sheared products were as an input control. The chromatin preparation was incubated with specific antibodies including anti-FoxO3a, anti-HNF-1α or control IgG (Millipore) at 4°C for 24 h. Quantitative real-time PCR was carried out to enrich the promoter binding levels determined using the PCSK9 ChIP primers 5'-TCCAGCCCAGTTAGGATTTG-3' and 5'-CGGAAACCTTCTAGGTTG-3' [14, 17]. The data were analyzed by ΔΔCt method [32] and expressed as fold enrichment (fold increase compared to the control IgG).

Statistical Analysis
All experiments were replicated at least three times, and the values are expressed as the mean ± SD. The results were analyzed using one-way ANOVA with Dunnet's post hoc test, and a p value < 0.05 was considered statistically significant.

Results
Effect of tanshinone IIA on the LDLR expression and LDLR activity
First, the cytotoxic effect of tanshinone IIA on HepG2 cells was examined. The cells were cultured in lipoprotein-deficient serum (LPDS)-containing medium and treated with vehicle (0.1% DMSO) or tanshinone IIA (1–20 μM) for 24 h. The cell viability was determined by MTT assay. As shown in Fig 1B, tanshinone IIA (1–20 μM) exerted no significant cytotoxicity
on HepG2 cells. We further investigated the effect of tanshinone IIA on the LDLR gene expression. As shown in Fig 2A and 2B, tanshinone IIA (5 and 10 μM) did not significantly change the LDLR mRNA expression or the transcriptional activity of the LDLR promoter in HepG2 cells. Furthermore, the effect of tanshinone IIA on LDLR protein expression were analyzed in HepG2 cells. Western blot analysis showed that the cellular LDLR proteins were significantly increased in the tanshinone IIA (5 and 10 μM)-treated cells compared to the vehicle control group (p < 0.01) (Fig 2C and 2D). Moreover, the effect of tanshinone IIA on HMG-CoA reductase (HMGCR) expression, a key enzyme for cholesterol biosynthesis, was also examined in HepG2 cells. As shown in Fig 2E, tanshinone IIA at concentration of 10 μM slightly decreased the HMGCR mRNA expression, however, cells treated with 5 μM tanshinone IIA expressed...
similar levels of HMGCR. These data indicate that tanshinone IIA modulates the LDLR expression may not be the result on the transcriptional regulation or inhibition of cholesterol biosynthesis.

Furthermore, the effect of tanshinone IIA on the level of cell-surface LDLR was investigated using flow cytometry analysis, as described in Materials and Methods section. As shown in Fig 3A and 3B, the cell-surface LDLR level on the HepG2 cells was significantly increased by approximately 40% and 60% in the tanshinone IIA (5 and 10 μM)-treated cells, respectively. The mean fluorescence intensity results showed that tanshinone IIA (5 and 10 μM)-treated cells markedly enhanced the LDL uptake by approximately 30% and 40% compared to the vehicle control (*p<0.01), respectively (Fig 3C and 3D). These above results suggest that tanshinone IIA increases the amount of LDLR protein at the post-transcriptional level and enhances the LDL uptake activity in the HepG2 cells.
Tanshinone IIA down-regulates the PCSK9 gene expression in HepG2 cells

PCSK9 protein is a known regulator for post-transcriptional modulation of LDLR in hepatic cells. Therefore, the effect of tanshinone IIA on PCSK9 gene expression was further investigated in HepG2 cells. As shown in Fig 4A, HepG2 cells treated with 5 and 10 μM tanshinone IIA significantly inhibited the PCSK9 mRNA expression by approximately 24% and 51% compared to the vehicle-treated group (p<0.01), respectively. We further examined the effect of tanshinone IIA on the transcriptional activity of PCSK9 promoter by transfecting cells with a PCSK9 promoter reporter plasmid (PCSK9-p(-1459/-4)) and a Renilla luciferase control plasmid. The results showed that tanshinone IIA significantly inhibited the transcriptional activity of the PCSK9 promoter (p<0.01).
plasmid, as described in Materials and Methods section. The result showed that the PCSK9 promoter activity was significantly reduced in the 5 and 10 μM tanshinone IIA-treated cells compared to the vehicle-treated cells (p<0.01) (Fig 4B). Furthermore, we examined the PCSK9 protein expression in tanshinone IIA-treated cells by western blot analysis. As shown in Fig 4C and 4D, tanshinone IIA significantly reduced the level of mature PCSK9 protein in HepG2 cells. These results indicate that tanshinone IIA-mediated PCSK9 down-regulation through the inhibition of the PCSK9 promoter activity.

Characterization of tanshinone IIA-responsive element upon PCSK9 promoter

To investigate the molecular mechanism underlying the tanshinone IIA-mediated PCSK9 down-regulation, the regulatory DNA elements of the PCSK9 promoter that are responsive to the tanshinone IIA-mediated PCSK9 reduction were further identified. HepG2 cells were transfected with reporter plasmids containing serial deletions of the PCSK9 promoter [17] (Fig 5A) followed by exposure with vehicle or tanshinone IIA (10 μM) for 24 h. As shown in Fig 5B, the luciferase activities of tanshinone IIA-treated cells were significantly decreased as compared to the vehicle-treated cells (p<0.01). Additionally, we found that the PCSK9 promoter activity was strongly attenuated in those cells transfected with the reporter plasmid PCSK9-p(-335/-4). These data indicate that the DNA region located between the -411 and -336 positions on PCSK9 proximal promoter is a critical regulatory element for tanshinone IIA-mediated PCSK9 down-regulation. It has been reported that this region of the PCSK9 promoter contains an

---

**Fig 5. Effect of tanshinone IIA on PCSK9 promoter activity.** (A) Serially deleted PCSK9 promoter reporter constructs. (B) HepG2 cells were transfected with the serial deleted PCSK9 promoter reporter constructs for 24 h and then treated with the vehicle (0.1% DMSO) or tanshinone IIA (10 μM) for 24 h. The luciferase activities were determined and normalized to their respective Renilla luciferase control activities. The data represent the mean ± SD from three independent experiments. **p<0.01 represents a significant difference compared to the pGL3-basic vector-transfected cells. ##p<0.01 represents a significant difference compared to the respective vehicle-treated group. (C) The analysis of the tanshinone IIA-response element within the PCSK9 promoter. The previously characterized HNF-1α, SREBP2 and FoxO3a binding sites are indicated as HNF-1α site, SRE and FoxO3a site, respectively.

doi:10.1371/journal.pone.0162414.g005
HNF-1α binding site, a SREBP2 binding element (sterol regulatory element; SRE), as well as a FoxO3α binding site [14, 15, 33] (Fig 5C).

Effects of tanshinone IIA on the nuclear HNF-1α, SREBP2 and FoxO3α proteins

To investigate whether these transcription factors are involved in the tanshinone IIA-mediated PCSK9 down-regulation, the effect of tanshinone IIA on the levels of nuclear HNF-1α, SREBP2 and FoxO3α proteins were evaluated in HepG2 cells. As shown in Fig 6A–6C, when the cells were treated with 5 or 10 μM tanshinone IIA, the nuclear HNF-1α level was not significantly altered in the HepG2 cells. However, tanshinone IIA (10 μM) slightly reduced the

Fig 6. Effect of tanshinone IIA on the nuclear accumulation of HNF-1α, SREBP2 and FoxO3α proteins. (A) Levels of nuclear HNF-1α and SREBP2 proteins measured by Western blot analysis. A representative blot is shown. The normalized intensities of HNF-1α (B) and SREBP2 (C) versus HDAC2 are presented as the mean ± SD of three independent experiments. *p<0.05 represents a significant difference compared to the vehicle-treated group. (D) The nuclear FoxO3α protein was detected by western blot analysis. A representative blot is shown. The normalized intensity of FoxO3α versus HDAC2 is presented as the mean ± SD of three independent experiments. **p<0.01 represents a significant difference compared to the vehicle-treated group. (E) The ChIP assay was performed as described in the Materials and Methods section. The PCSK9 promoter complex was measured by RT-Q-PCR. The data were expressed as the fold enrichment of the FoxO3α antibody (FoxO3α Ab) or HNF-1α antibody (HNF-1A Ab) over the control IgG. The data represent the mean ± SD from three independent experiments. # p<0.05 and ## p<0.01 represents a significant difference compared to the vehicle-treated control IgG group.

doi:10.1371/journal.pone.0162414.g006
nuclear SREBP2 protein in HepG2 cells. We further detected the nuclear accumulation of FoxO3a in 5 or 10 μM tanshinone IIA-treated HepG2 cells. The level of nuclear FoxO3a protein was significantly increased by 2.9- and 4.0-fold compared to the vehicle-treated cells, respectively (Fig 6D). Furthermore, the effect of tanshinone IIA on the in vivo interaction of FoxO3a with the PCSK9 promoter in HepG2 cells was examined using a ChIP assay, as described in Materials and Methods section. As shown in Fig 6E, cells were treated with tanshinone IIA (10 μM) significantly increased the FoxO3a/PCSK9 promoter complexes formation compared to the vehicle-treated cells. Additionally, we examined the effect of tanshinone IIA on the interaction of HNF-1α and PCSK9 promoter. We found that the nuclear HNF-1α/PCSK9 promoter complexes formation was significantly attenuated in tanshinone IIA-treated cells. These above results suggest that tanshinone IIA increases the accumulation of nuclear FoxO3a protein and its interaction with the PCSK9 promoter, which may lead to reduce the promoter binding capacity of HNF-1α and down-regulate the PCSK9 gene expression in HepG2 cells.

Combination of tanshinone IIA and statins treatment promotes more LDL uptake in HepG2 cells

Statin treatment may increase the PCSK9 gene expression and attenuate the therapeutic ability for lowering the plasma LDL, thus, we further investigated whether a combination of tanshinone IIA and statins alter the PCSK9 expression and LDL uptake in HepG2 cells. The cytotoxic effect of a tanshinone IIA and statins combination was evaluated in HepG2 cells. As shown in Fig 7A, the combination of tanshinone IIA (10 μM) and lovastatin or simvastatin (1 μM) treatment showed no cytotoxicity on HepG2 cells. The cells treated with lovastatin or simvastatin...
alone significantly increased PCSK9 mRNA and mature protein expression (Figs 7B and 8A). The lovastatin- or simvastatin-induced PCSK9 expression were significantly attenuated by co-treatment with tanshinone IIA. As shown in Fig 8B, co-treatment of cells with tanshinone IIA and two statins significantly increased the LDL uptake activity as compared to cells treated with lovastatin or simvastatin alone. Our results reveal that a combination of tanshinone IIA and statins markedly attenuated the statin-induced PCSK9 gene expression and elevated LDLR activity in HepG2 cells.

Discussion
In the present study, we demonstrate that tanshinone IIA markedly down-regulates PCSK9 gene expression, which is associated with increases in the amount of cell-surface LDLR and its LDL-uptake activity in HepG2 cells. We show that tanshinone IIA dramatically elevates the nuclear abundance of the FoxO3a and its interaction with PCSK9 promoter, which may result in the inhibition of HNF-1α/PCSK9 promoter complex formation and the down-regulation of
PCSK9 gene expression (Fig 9). Moreover, we demonstrate that tanshinone IIA attenuates the lovastatin- or simvastatin-induced PCSK9 expression and potentially combines treatment with statins.

The hepatic LDLR expression is involved in the regulation of plasma cholesterol homeostasis. It is known that patients with familial hypercholesterolemia, commonly mutations in the LDLR, experience high levels of LDL-C and premature atherosclerosis [34]. Elevated LDLR expression in hepatic cells results in increased clearance of plasma LDL through LDLR-mediated endocytosis and is associated with a decreased risk of cardiovascular disease [35, 36]. In the present study, we demonstrated that tanshinone IIA significantly increases the levels of total cellular and cell-surface LDLR protein and its LDL uptake activity in HepG2 cells. Our finding supported that tanshinone IIA possesses a cholesterol-lowering effect and has great potential for the prevention or treatment of hypercholesterolemia. The LDLR gene expression is transcriptionally activated by the sterol regulatory element binding proteins (SREBPs) [37]. We further investigated the effect of tanshinone IIA on the LDLR transcription in HepG2 cells. We found that the LDLR promoter activity and mRNA expression were not significantly altered by tanshinone IIA treatment in HepG2 cells. Our findings indicate that tanshinone IIA increases the level of hepatic LDLR protein at post-transcriptional regulation, not through transcriptional activation.

In addition to transcriptional control, the LDLR is also modulated by PCSK9 or the inducible degrader of LDLR (IDOL) at post-transcriptional regulation [38, 39]. The PCSK9 and IDOL proteins decrease the LDLR abundance and reduce LDL uptake into liver cells. The
extracellular mature PCSK9 protein has been demonstrated to bind the epidermal growth factor-like repeat A (EGF-A) domain of LDLR, which leads to internalization, impedes LDLR recycling and delivers LDLR to the lysosome for degradation [40]. The overexpression of PCSK9 or PCSK9-knockout mice shows an inverse relationship between LDLR and PCSK9 levels, indicating that PCSK9 protein also controls the plasma cholesterol homeostasis [41, 42]. Thus, we next investigated the effect of tanshinone IIA on PCSK9 expression in HepG2 cells. In the present study, we found that tanshinone IIA markedly inhibits the PCSK9 promoter activity and decreases the levels of PCSK9 mRNA and mature protein. Our current findings suggested that tanshinone IIA mediates the inhibition of PCSK9 expression, which leads to enhance the cell-surface LDLR and its LDL-uptake activity. PCSK9 inhibition therapy through monoclonal antibodies or small interfering RNA (siRNA) leads to higher levels of hepatic LDLR, lower circulating LDL-C levels, and improved cardiovascular disorder outcomes and does not show any adverse side-effects [43–45]. In the present study, the inhibition of PCSK9 gene expression by tanshinone IIA might be expected to serve as a novel approach to cholesterol management. In addition to PCSK9, E3-ubiquitin ligase IDOL protein has been reported to share the same LDLR substrate, although it has a distinct mechanism in modulating the LDLR abundance at the post-translational level [39]. In the present study, we found that the level of IDOL mRNA was decreased by approximately 35%, although the IDOL protein expression was slightly reduced in the tanshinone IIA (10 μM)-treated HepG2 cells (data not shown). The effect of tanshinone IIA on the IDOL-mediated LDLR modulation remains to be further investigated. Our current findings suggested that tanshinone IIA significantly increases the LDLR amount through the down-regulation of PCSK9 expression.

In the present study, we demonstrated that the PCSK9 mRNA is down-regulated by tanshinone IIA through the inhibition of promoter activity. The tanshinone IIA-responsive element was characterized and defined to the proximal promoter region (-411 to -336). Within this region of the PCSK9 promoter, there are three potential transcriptional factor binding sites, including the HNF-1α binding element [46], the sterol regulatory element for SREBP2 interaction [46] and FoxO3a binding site [15] that have been identified. We further analyzed the nuclear amounts of HNF-1α, SREBP2 and FoxO3a in tanshinone IIA-treated HepG2 cells. We found that tanshinone IIA (10 μM) slightly reduced nuclear SREBP2 level and dramatically enhanced the nuclear amount of FoxO3a in HepG2 cells. Our data revealed that FoxO3a plays a major role in the tanshinone IIA-mediated PCSK9 transcriptional suppression. The FoxO3a protein is reported to be an important transcription factor and is associated with several essential cellular functions including cell proliferation, apoptosis, metabolism, stress resistance and longevity in several cell types [47, 48]. Tao et al. reported that FoxO3 overexpression improves hypercholesterolemia in obese mouse models. The FoxO3 protein has been demonstrated to coordinate with NAD⁺-dependent deacetylase sirtuin 6 (Sirt6) for the suppression of SREBP2 expression and modulation of cholesterol biosynthesis in a mouse model [49]. In addition to regulate the SREBP2, FoxO3a has been reported to recruit Sirt6 to the proximal promoter region of PCSK9 and result in the deacetylation of histones H3 at lysine 9 (H3K9) and lysine 56 (H3K56), a repressed state of the chromatin of PCSK9 gene, to suppress the HNF-1α-mediated transcriptional activation, which leads to the down-regulation of PCSK9 mRNA expression [15]. In this study, we found that the accumulation of nuclear FoxO3a protein was markedly increased by tanshinone IIA in a dose-dependent manner in HepG2 cells. We demonstrated that tanshinone IIA increased the FoxO3a/PCSK9 promoter binding capacity in HepG2 cells. Moreover, we found that the level of nuclear HNF-1α protein was not altered, however, the PCSK9 promoter binding capacity of HNF-1α was significantly reduced in tanshinone IIA-treated cells. Our current findings supported that treatment of cells with tanshinone IIA causes an increase in nuclear FoxO3a protein accumulation may recruit Sirt6.
deacetylase to promote histones modification, which leads to suppress the promoter-binding capacity of nuclear HNF-1α for PCSK9 transcription. Plas et al. reported that the FoxO3a is phosphorylated by protein kinase B (Akt) and is mainly retained in the cytoplasm for degradation, which decreases the transcriptional activity [50]. Nho et al. reported that the de-phosphorylation of FoxO3a by protein phosphatase-2A (PP2A) results in promoting its translocation to the nucleus [51]. Whether tanshinone IIA affects the kinase or phosphatase activity to increase the nuclear accumulation of FoxO3a protein needs to be further investigated.

Statins and ezetimibe are the most common and effective drugs for lowering plasma cholesterol levels and improving outcomes from coronary artery diseases [52–54]. Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, reduce cholesterol levels by inhibiting cholesterol biosynthesis. Statins have been reported to increase the LDLR mRNA level and to enhance the clearance of plasma cholesterol. However, statin therapy has some limitations including intolerance to statin treatment and increased plasma levels of PCSK9 [55, 56]. Statins increase PCSK9 as well as LDLR expression, which compromise the effect of the increased LDLR levels counteracting the ability to reduce the plasma LDL-cholesterol levels. In the present study, tanshinone IIA attenuated lovastatin- or simvastatin-induced PCSK9 mRNA and protein expression. Moreover, a combination of tanshinone IIA and lovastatin or simvastatin dramatically enhanced the LDL-uptake by HepG2 cells. Our results suggest that tanshinone IIA effectively reduces PCSK9 expression and could be used as an effective supplement to statin therapy for greater suppression of LDL-C.

In conclusion, we report that tanshinone IIA exerts the promising effect of PCSK9 down-regulation. Our data elucidates that tanshinone IIA mediates the suppression of PCSK9 in a FoxO3a-related manner, leading to an increase in LDL uptake in hepatic cells. Our findings provide a molecular basis of tanshinone IIA for the development of PCSK9 inhibitors for cholesterol homeostasis maintenance.

Author Contributions

Conceptualization: PYC MJW JHY.
Data curation: HCC PYC JHY.
Formal analysis: HCC PYC.
Funding acquisition: MJW JHY.
Investigation: HCC PYC MHT JHY.
Methodology: HCC MJW MHT JHY.
Project administration: PYC JHY.
Resources: PYC MJW JHY.
Supervision: JHY.
Validation: HCC PYC MHT.
Visualization: HCC PYC JHY.
Writing – original draft: HCC PYC MHT JHY.
Writing – review & editing: HCC PYC MJW JHY.
References

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1; 123(4): e18–e209. doi: 10.1161/CIR.0b013e3182009701 PMID: 21160056

2. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011 Jun; 32(11):1345–61. doi: 10.1093/eurheartj/ehr12 PMID: 21531743

3. Beglova N, Blacklow SC. The LDL receptor: how acid pulls the trigger. Trends Biochem Sci. 2005 Jun; 30(6):309–17. PMID: 15950875

4. Gent J, Braakman I. Low-density lipoprotein receptor structure and folding. Cell Mol Life Sci. 2004 Oct; 61(19–20):2461–70. PMID: 15526154

5. Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med. 2012 Mar; 85(1):19–28. PMID: 22461740

6. Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014 Oct; 25(5):387–93. doi: 10.1097/MOL.0000000000000114 PMID: 25110901

7. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004 Nov 19; 279(47):48865–75. PMID: 15358785

8. Costet P, Krempf M, Carrou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci. 2008 Sep; 33(9):426–34. doi: 10.1016/j.tibs.2008.06.005 PMID: 18672372

9. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006 Mar 23; 354(12):1264–72. PMID: 16554528

10. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013 Mar; 15(3):310. doi: 10.1007/s11883-013-0310-3 PMID: 23371064

11. Lopez D. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia. Drug News Perspect. 2008 Jul-Aug; 21(6):326–30. doi: 10.1358/dnp.2008.21.6.1246795 PMID: 18836590

12. Giunzioni I, Tavori H. New developments in atherosclerosis: clinical potential of PCSK9 inhibition. Vasc Health Risk Manag. 2015; 11:493–501. doi: 10.2147/VHRM.S74692 PMID: 26345307

13. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A. 2003 Oct 14; 100(21):12027–32. PMID: 14512514

14. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009 Oct 16; 284(42):28885–95. doi: 10.1074/jbc.M109.052407 PMID: 19687008

15. Tao R, Xiong X, DePinho RA, Deng CX, Dong XC. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem. 2013 Oct 11; 288(41):29252–9. doi: 10.1074/jbc.M113.481473 PMID: 23974119

16. Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res. 2003 Nov; 44(11):2109–19. PMID: 12897189

17. Tai MH, Chen PK, Chen PY, Wu MJ, Ho CT, Yen JH. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol Nutr Food Res. 2014 Nov; 58(11):2133–45. doi: 10.1002/mnr.201403666 PMID: 25164566

18. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005 Dec; 45(12):1345–59. PMID: 16291709

19. Han JY, Fan JY, Horie Y, Miura S, Cui DH, Ishii H, et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther. 2008 Feb; 117(2):280–95. PMID: 18048101

20. Chen Z, Xu H. Anti-Inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis. Evid Based Complement Alternat Med. 2014; 2014:267976. doi: 10.1155/2014/267976 PMID: 25525444

21. Shang Q, Xu H, Huang L. Tanshinone IIA: A Promising Natural Cardioprotective Agent. Evid Based Complement Alternat Med. 2012; 2012:716459. doi: 10.1155/2012/716459 PMID: 22454677
22. Tang F, Wu X, Wang T, Wang P, Li R, Zhang H, et al. Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. Vascul Pharmacol. 2007 Jun; 46(6):427–38. PMID: 17337361

23. Chen W, Tang F, Xie B, Chen S, Huang H, Liu P. Amelioration of atherosclerosis by tanshinone II in hyperlipidemic rabbits through attenuation of oxidative stress. Eur J Pharmacol. 2012 Jan 15; 674(2–3):359–64. doi: 10.1016/j.ejphar.2011.10.040 PMID: 22088276

24. Xu S, Liu Z, Huang Y, Le K, Tang F, Huang H, et al. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-kappaB activation. Transl Res. 2012 Aug; 160(2):114–24. doi: 10.1016/j.trsl.2012.01.008 PMID: 22677363

25. Liu Z, Wang J, Huang E, Gao S, Li H, Lu J, et al. Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. J Lipid Res. 2014 Feb; 55(2):201–13. doi: 10.1194/jlr.M040394 PMID: 24302760

26. Meex SJ, Andreo U, Sparks JD, Fisher EA. Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J Lipid Res. 2011 Jan; 52(1):152–8. doi: 10.1194/jlr.D008888 PMID: 20956548

27. Harwood HJ Jr, Pellarin LD. Kinetics of low-density lipoprotein receptor activity in Hep-G2 cells: derivation and validation of a Briggs-Haldane-based kinetic model for evaluating receptor-mediated endocytotic processes in which receptors recycle. Biochem J. 1997 May 1; 323 (Pt 3):649–59. PMID: 9169597

28. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15; 47 (4):936–42. PMID: 3802100

29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec; 25(4):402–8. PMID: 11846609

30. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009 Jul 3; 325(5936):100–4. doi: 10.1126/science.1168974 PMID: 19520913

31. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007 Feb; 32(2):71–7. PMID: 17215125
43. Blom DJ, Haia T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8; 370(19):1809–19. doi: 10.1056/NEJMoa1316222 PMID: 24678979

44. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014 Jan 4; 383(9911):60–8. doi: 10.1016/S0140-6736(13)61914-5 PMID: 24094767

45. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011 Jun; 216(2):258–65. doi: 10.1016/j.atherosclerosis.2011.04.018 PMID: 21596380

46. Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010 Jun; 51(6):1486–95. doi: 10.1194/jlr.M003566 PMID: 20048381

47. Nho RS, Hergert P. FoxO3a and disease progression. World J Biol Chem. 2014 Aug 26; 5(3):346–54. doi: 10.4331/wjbc.v5.i3.346 PMID: 25225602

48. van der Vos KE, Coffer PJ. The extending network of FOXO transcriptional target genes. Antioxid Redox Signal. 2011 Feb 15; 14(4):579–92. doi: 10.1089/ars.2010.3419 PMID: 20673124

49. Tao R, Xiong X, DePinho RA, Dong XC. Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6. J Lipid Res. 2013 Oct; 54(10):2745–53. doi: 10.1194/jlr.M039339 PMID: 23881913

50. Plas DR, Thompson CB. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem. 2003 Apr 4; 278(14):12361–6. PMID: 12517744

51. Nho RS, Kahm J. beta1-Integrin-collagen interaction suppresses FoxO3a by the coordination of Akt and PP2A. J Biol Chem. 2010 May 7; 285(19):14196–209. doi: 10.1074/jbc.M109.052845 PMID: 20223831

52. Smith BA, Wright C, Davidson M. Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Curr Atheroscler Rep. 2015 Dec; 17(12):72. doi: 10.1007/s11883-015-0550-5 PMID: 26490081

53. Battaggia A, Donzelli A, Font M, Molteni D, Galvano A. Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015; 10(4):e0124587. doi: 10.1371/journal.pone.0124587 PMID: 25915909

54. Miller PE, Martin SS. Approach to Statin Use in 2016: an Update. Curr Atheroscler Rep. 2016 May; 18(5):20. doi: 10.1007/s11883-016-0578-1 PMID: 26973129

55. Careskey HE, Davis RA, Albom WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008 Feb; 49(2):394–8. PMID: 18033751

56. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol. 2012 Sep 6; 159(3):169–76. doi: 10.1016/j.ijcard.2011.07.048 PMID: 21813193